Cargando…
Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce DMD Exon 2 Skipping
Therapeutic exon skipping as a treatment for Duchenne muscular dystrophy (DMD) has largely concentrated on the delivery of antisense oligomers to treat out-of-frame exon deletions. Here we report on the preclinical development of an adeno-associated virus (AAV)-encapsidated viral vector containing f...
Autores principales: | Gushchina, Liubov V., Frair, Emma C., Rohan, Natalie, Bradley, Adrienne J., Simmons, Tabatha R., Chavan, Hemantkumar D., Chou, Hsin-Jung, Eggers, Michelle, Waldrop, Megan A., Wein, Nicolas, Flanigan, Kevin M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112461/ https://www.ncbi.nlm.nih.gov/pubmed/33406986 http://dx.doi.org/10.1089/hum.2020.286 |
Ejemplares similares
-
Persistence of exon 2 skipping and dystrophin expression at 18 months after U7snRNA-mediated therapy in the Dup2 mouse model
por: Gushchina, Liubov V., et al.
Publicado: (2023) -
Pre-clinical dose-escalation studies establish a therapeutic range for U7snRNA-mediated DMD exon 2 skipping
por: Simmons, Tabatha R., et al.
Publicado: (2021) -
Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse
por: Wein, Nicolas, et al.
Publicado: (2022) -
Exon skipping for DMD
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2012) -
Skipping Multiple Exons to Treat DMD—Promises and Challenges
por: Aslesh, Tejal, et al.
Publicado: (2018)